Evidence map›Paper›PMID 26088461›Full record

ArticleJournal of neuro-oncology2015

Nrdp1-mediated ErbB3 degradation inhibits glioma cell migration and invasion by reducing cytoplasmic localization of p27(Kip1).

Hengliang Shi, Hui Gong, Kuan Cao, Shenshan Zou, Bingxin Zhu, Hanmo Bao, Yuxuan Wu, Yong Gao, Yuan Tang, Rutong Yu

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. mCell death & disease · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Ubiquitin ligaseOncology letters · 2019
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Hengliang ShiInsititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Hui GongThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Kuan CaoThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Shenshan ZouThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Bingxin ZhuThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Hanmo BaoThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Yuxuan WuThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Yong GaoThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Yuan TangThe Graduate School, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China.
Rutong YuInsititute of Nervous System Diseases, Xuzhou Medical College, Xuzhou, Jiangsu, People's Republic of China. yu.rutong@163.com.
Xuzhou Medical College · CNAffiliated Hospital of Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported that loss of Nrdp1 contributes to human glioma progression by reducing apoptosis. However, the role of Nrdp1 in glioma migration and invasion has not been investigated. Here, we report that ErbB3, a substrate of Nrdp1, is undetectable in normal brain tissues and grade II/III glioma tissues, but is abundant in a certain percentage of grade IV glioma tissues and is associated with the loss of Nrdp1. This suggests that Nrdp1 may be involved in glioma migration and invasion by regulating ErbB3. Thus, the role of Nrdp1/ErbB3 signaling in glioma cell migration and invasion was investigated using Nrdp1 loss- and gain-of-function. The results show that down-regulation of Nrdp1 by use of short hairpin RNA promoted glioma cell migration and invasion. In contrast, overexpression of Nrdp1 significantly inhibited glioma cell migration and invasion. Further investigation on molecular targets revealed that Nrdp1 decreased the level of ErbB3, which resulted in decreasing p-AKT thereby reducing cytoplasmic p27(Kip1). Taken together, these findings suggest that Nrdp1-mediated ErbB3 degradation suppresses glioma migration and invasion and that loss of Nrdp1 may amplify ErbB3 signaling to contribute to glioma migration and invasion. These findings suggest that Nrdp1 may be a target for glioma therapy.

Indexed as

Brain NeoplasmsCell Line, TumorCell MovementCyclin-Dependent Kinase Inhibitor p27Gene Expression Regulation, NeoplasticGliomaHumansNeoplasm InvasivenessReceptor, ErbB-3RetroviridaeTransfectionUbiquitin-Protein LigasesCDKN1B protein, humanCyclin-Dependent Kinase Inhibitor p27ERBB3 protein, humanReceptor, ErbB-3RNF41 protein, humanUbiquitin-Protein LigasesErbB3GliomaNrdp1p27Kip1PI3K

Identifiers

PMID26088461
OpenAlexW1590891892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.